FOSUN PHARMA

复星医药

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海復星醫藥(集團)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號:02196)

NOTIFICATION LETTER 通知信函

29 September 2025

Dear Registered Shareholders.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company")

— Notice of publication of circular of the 2025 first extraordinary general meeting, notice of the 2025 first extraordinary general meeting and form of proxy (collectively the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website (www.fosunpharma.com) and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (www.hkexnews.hk) respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note). If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed.

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's H share registrar and transfer office in Hong Kong, Tricor Investor Services Limited ("H Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to is-ecom@vistra.com. The Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the H Share Registrar at the above-mentioned address by post or by email to is-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the H Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications ("Notice of Publication") and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the H Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

By Order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Note: Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東:

上海復星醫藥(集團)股份有限公司(「本公司」)

<mark>一2025</mark>年第一次臨時股東會通函、2<mark>025</mark>年第一次臨時股東會通告及代表委任表格(統稱「是次公司通訊」)之登載通知

本公司的是次公司通訊之中、英文版本已分別上載於本公司網站(www.fosunpharma.com)及香港聯合交易所有限公司(「**聯交所**」)之網站(www.hkexnews.hk) (「網站版本」)。我們建議 閣下閱覽本公司是次及日後公司通訊^{網達)}的網站版本。如 閣下已選擇收取公司通訊的印刷本,隨函附上是次公司通訊。

如 閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本,及欲索取是次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附之回條,並以已預付郵費的郵寄標籤寄回本公司之H股股份過戶登記處(「H股股份過戶登記處」)卓佳證券登記有限公司(地址為香港夏慤道16號遠東金融中心17樓)(如在香港投寄毋須貼上郵票),或電郵至is-ecom@vistra.com。本公司會因應 閣下之要求立即寄上是次公司通訊的印刷本,費用全免。

登記股東有責任提供有效的電子郵件地址。如 閣下尚未提供 閣下之電子郵件地址予本公司,或需更新 閣下之電子郵件地址,本公司建議 閣下填妥及簽署隨附之回條,並按上述地址以郵寄方式交回本公司的H股股份過戶登記處或以電郵方式發送至is-ecom@vistra.com。如果本公司沒有收到 閣下的有效電子郵件地址,直至H股股份過戶登記處收到 閣下有效的電子郵件地址前, 閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本公司將只能以印刷本方式向 閣下發送登載通知及可供採取行動的公司通訊之印刷本予 閣下。

倘 閣下對本通知有任何查詢,請於辦公時間星期一至星期五(公眾假期除外)上午9時至下午6時,致電H股股份過戶登記處熱線(852)29801333。

承董事會命 上海復星醫藥(集團)股份有限公司 陳玉卿 董事長

2025年9月29日

附註: 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度賬目連同核數師報告以及財務摘要報告(如適用);(b)中期報告及中期摘要報告(如適用);(c)會議通告;(d)上市文件;(e)通函;(f)代表委任表格;及(g)可供採取行動的公司通訊。

REPL	YI	ORI	M	回條
------	----	-----	---	----

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") (Stock Code: 02196)

(A joint stock company incorporated in the People's Republic of China with limited liability) c/o Tricor Investor Services Limited

17/F, Far East Finance Centre

16 Harcourt Road, Hong Kong

上海復星醫藥(集團)股份有限公司 (「本公司」)(股份代號:02196)

(於中華人民共和國註冊成立的股份有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓

Part A 甲部
Please mark "✓" in ONLY ONE of the following boxes 請從下列選擇中,僅在其中一個空格內劃上「✓」號)
to receive the printed copy in the English language only; OR 收取英文印刷本;或 to receive the printed copy in the Chinese language only; OR 收取中文印刷本;或 to receive the printed copy in both the English language and the Chinese language. 收取英文及中文印刷本。
Part B
Please provide the email address in English BLOCK LETTERS) 請以英文正楷填寫電子郵件地址)
Name(s) of Shareholder(s): (Please use English BLOCK LETTERS) Signature: 皮東姓名: (請用英文正楷填寫) 簽名:
Address: (Please use English BLOCK LETTERS

地址:

(請用英文正楷填寫)

Contact telephone number: Date: 聯絡電話號碼: 日期

Notes 附註:

accounts togetner win a copy or me adultors report and, where application, where application, common processing the form; and (g) Actionable Corporate Communications.
公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度賬目連同核數師報告以及(如適用)財務摘要報告;(b)中期報告及(如適用)中期損要報告;(c)會議通告;(c)會議通告;(c)自議通告;(d)上市文件;(c)通通;(f)代表委任表格,及(g)可供採取行動的公司通訊。
Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.
可供採取行動的公司通訊是指任何涉及要求股東指示其餐如何行使其有關股東權利的公司通訊。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明
"Personal Data" in this statement has the same meaning as "personal data" defined in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). Your supply of the Personal Data is on a voluntary basis and for the purpose of processing your instructions as stated in this form (the "Purposes"). If you fail to supply sufficient information, the Company may not be able to process your instructions. The Company may disclose or transfer the Personal Data to its subsidiaries, its H share registrar and/or third party service provider who provides administrative, computer and other services to the Company may disclose or transfer the Personal Data to its substitutines, its H share registrar and/or infrid party service provider who provider and administrative, computer and other services to the Company for use in connection with the Purposes and to such parties who are authorised by law to request the information or are otherwise relevant for the Purposes and need to receive the information. The Personal Data will be retained for such period as may be necessary to fulfill the Purposes (including for verification and record purposes). Request for access to and/or correction of the Personal Data can be made in accordance with the provisions of the PDPO and any such request should be in writing and sent to the Data Privacy Officer of Tricor Investor Services Limited at the above address.

Finacy Office of Tricor investor services Limited at the above address.

本聲明中所指的「個人資料」與香港法例第486章《個人資料(私隱)條例》(「《個人資料(私隱)條例》」)中「個人資料」的涵義相同。 閣下是自願提供個人資料,以用於處理 閣下在本回條上所述的指示(「該等用途」)。如 閣下未能提供足夠資料,本公司有可能無法處理 閣下的指示。本公司可就所述的該等用途,將個人資料披露或轉移給本公司的附屬公司、H股股份過戶登記處及/或向為本公司提供行政、電腦及其他服務的第三者服務供應商,以及其他獲法例授權而要求取得有關資料的人士或其他與上述所列出的該等用途有關以及需要接收有關資料之人士。個人資料將在適當期間保留作履行所述的該等用途(包括作核實及紀錄用途)。有關查閱及/或更正個人資料的要求可按照《個人資料(私隱)條例》提出,而有關要求須以書面方式郵寄至卓佳證券登記有限公司(地址如上)的個人資料私隱主任。

Ж

Please cut the mailing label and stick it on an envelope

to return this Reply Form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回本回條時,請將郵寄標籤剪貼於信封上。

如在本港投寄, 閣下無需支付郵費或貼上郵票。

Mailing Label 郵寄標籤

Tricor Investor Services Limited 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼:10 GPO Hong Kong 香港